- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 18.03. | H.C. Wainwright cuts OnKure Therapeutics price target to $34 | 1 | Investing.com | ||
| ONKURE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 10.03. | OnKure Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 10.03. | OnKure Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 10.03. | OnKure Therapeutics, Inc.: OnKure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights | 184 | GlobeNewswire (Europe) | - PIKture-01 trial update including additional PK data, mature single agent and initial combination data expected in the second half of 2025; reported encouraging preliminary data in December 2024... ► Artikel lesen | |
| 10.03. | OnKure Therapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 10.12.24 | OnKure reports positive early trial data for cancer drug OKI-219 | 1 | Investing.com | ||
| 10.12.24 | OnKure meldet positive frühe Studiendaten für Krebsmedikament OKI-219 | 3 | Investing.com Deutsch | ||
| 10.12.24 | OnKure Therapeutics, Inc.: OnKure Announces Encouraging Preliminary Safety, Tolerability, and Pharmacokinetic (PK) Data from its First-In-Human PIKture-01 Trial of OKI-219 | 126 | GlobeNewswire (Europe) | -- OKI-219 is well-tolerated across all doses, and no dose interruptions, delays, reductions, or discontinuations were reported -- Initial patient data show exposures of OKI-219 exceeding levels associated... ► Artikel lesen | |
| 10.12.24 | OnKure Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 09.12.24 | OnKure Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 25.11.24 | OnKure Therapeutics, Inc.: OnKure Announces New Date for Upcoming Investor Call | 3 | GlobeNewswire (USA) | ||
| 07.11.24 | OnKure Therapeutics announces accounting firm change | 5 | Investing.com | ||
| 07.11.24 | OnKure Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 07.11.24 | OnKure Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 01.11.24 | OnKure Therapeutics, Inc.: OnKure to Present Clinical and Preclinical Data for OKI-219 at the 2024 San Antonio Breast Cancer Symposium | 2 | GlobeNewswire (USA) | ||
| 04.10.24 | OnKure Therapeutics, Inc. Announces Closing of Merger with Reneo Pharmaceuticals and Concurrent Private Placement of $65 Million | 230 | GlobeNewswire (Europe) | -- OnKure is focused on advancing a pipeline of candidates targeting oncogenic mutations in phosphoinositide 3-kinase alpha (PI3Ka), initially in breast cancer -- On track to announce early clinical... ► Artikel lesen | |
| 03.10.24 | Reneo Pharmaceuticals, Inc.: Reneo Pharmaceuticals Announces Stockholder Approval of Merger with OnKure | 205 | GlobeNewswire (Europe) | - Combined company to trade on Nasdaq under ticker "OKUR" - Reneo announces 1-for-10 reverse split of common stock IRVINE, Calif., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq:... ► Artikel lesen | |
| 13.05.24 | Reneo Pharmaceuticals, Inc. and OnKure Announce Proposed Merger | 405 | GlobeNewswire (Europe) | Merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing OnKure's portfolio of novel precision medicines in oncology
Combined company is expected to have approximately... ► Artikel lesen | |
| 07.05.24 | Reneo Pharmaceuticals, Inc.: Reneo Pharmaceuticals Reports First Quarter 2024 Financial Results | 385 | GlobeNewswire (Europe) | IRVINE, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a pharmaceutical company historically focused on the development and commercialization of therapies for... ► Artikel lesen |
19 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 20,095 | +1,69 % | Blockbuster oder Übernahmefieber? Warum Novo Nordisk, Defence Therapeutics und Pfizer jetzt alle Blicke auf sich ziehen | Die Biotech- und Pharmabranche gleicht einem Schachbrett der Milliarden! Ein einziger Zug - ob Übernahme oder Zulassung - kann Aktienkurse in Stunden verdoppeln oder ganze Märkte neu ordnen. Während... ► Artikel lesen | |
| SANOFI | 93,33 | -0,07 % | Aktienmarkt: Kurs der Sanofi SA-Aktie im Minus (89,69 €) | Die Sanofi SA-Aktie notiert heute etwas leichter. Das Papier kostete zuletzt 89,69 Euro. Die Aktie von Sanofi SA verzeichnet derzeit einen Abschlag von 0,80 Prozent. Sie hat sich um 72 Cent gegenüber... ► Artikel lesen | |
| INNOCAN PHARMA | 0,103 | -2,83 % | InnoCan Pharma Aktie: Kapitalspritze mit Beigeschmack | InnoCan Pharma schließt Privatplatzierung ab, doch die Finanzspritze könnte bestehende Aktionäre verwässern. Der Aktienkurs fällt weiter. Die Aktie von InnoCan Pharma verliert heute deutlich und notiert... ► Artikel lesen | |
| ASSEMBLY BIOSCIENCES | 9,440 | +2,39 % | Assembly Biosciences Aktie: Erfolgreicher Neustart gelingt! | Das Biotech-Unternehmen entwickelt innovative Therapeutika gegen Viruserkrankungen und stärkt seine Marktposition durch strategische Partnerschaften und klinische Studien. Assembly Biosciences zieht... ► Artikel lesen | |
| NEKTAR THERAPEUTICS | 0,607 | +0,50 % | Nektar Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results | SAN FRANCISCO, March 12, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter ended December 31, 2024.
Cash... ► Artikel lesen | |
| JAGUAR HEALTH | 6,610 | 0,00 % | Jaguar Health, Inc.: Proof-of-Concept Data for Rare Disease Indications MVID and SBS-IF for Jaguar Health's Crofelemer to be Presented at April 2025 ELITE PED-GI Congress | Crofelemer, a novel plant-based anti-secretory prescription drug, has been granted Orphan Drug Designation by the FDA and the European Medicines Agency (EMA) for both short bowel syndrome (SBS) and... ► Artikel lesen | |
| ROYALTY PHARMA | 27,970 | +0,04 % | Royalty Pharma declares $0.22 dividend | ||
| BRIDGEBIO PHARMA | 31,300 | +0,68 % | BridgeBio Pharma, Inc.: BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | PALO ALTO, Calif., April 11, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage biopharmaceutical company focused on genetic diseases... ► Artikel lesen | |
| CORBUS PHARMACEUTICALS | 7,150 | +10,00 % | Corbus Pharmaceuticals Holdings, Inc.: Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of Obesity | CB1 inverse agonism is a clinically validated mechanism to induce weight loss CRB-913 is markedly more peripherally restricted compared to monlunabant and rimonabantSAD/MAD Phase 1 trial scheduled... ► Artikel lesen | |
| SOLIGENIX | 2,040 | 0,00 % | Soligenix reports positive results in skin cancer treatment trial | ||
| KALA BIO | 2,668 | -4,37 % | KALA BIO, Inc.: KALA BIO Announces Chief Executive Officer Transition | ARLINGTON, Mass., Feb. 12, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative... ► Artikel lesen | |
| ACLARIS THERAPEUTICS | 1,095 | +4,64 % | Aclaris Therapeutics, Inc.: Aclaris Therapeutics Secures U.S. Food and Drug Administration IND Clearance for ATI-052, Enabling Advancement of its Novel Bispecific Anti-TSLP/IL-4R Investigational Antibody | - Initiation of Upcoming Phase 1a/1b Clinical Trial Expected in the Second Quarter of 2025 - WAYNE, Pa, April 22, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage... ► Artikel lesen | |
| NEUROGENE | 10,220 | -24,91 % | XFRA NEW INSTRUMENTS AVAILABLE ON XETRA - 20.11.2024 | The following instruments on XETRA do have their first trading 20.11.2024 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 20.11.2024
Aktien
1 PLRNBWT00031 Rainbow Tours S.A.
2... ► Artikel lesen | |
| ESSA PHARMA | 1,815 | +3,12 % | Essa Pharma Inc. Reports Results Of Annual General Meeting Of Shareholders | SOUTH SAN FRANCISCO, USA and VANCOUVER, Canada, March 6, 2025 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX), a pharmaceutical company... ► Artikel lesen | |
| LYRA THERAPEUTICS | 0,095 | +2,37 % | Lyra Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update | Company continues to focus on upcoming results from ENLIGHTEN 2 pivotal Phase 3 trial in CRS patients, expected in 2Q 2025In parallel, the Company continues to analyze data and explore opportunities... ► Artikel lesen |
ONKURE THERAPEUTICS INC gehört der Branche Pharma an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 2,720 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ONKURE THERAPEUTICS INC finden Sie auf Wallstreet Online.
